Related Experiment Video
Updated: Feb 1, 2026

Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models
Published on: October 28, 2021
Targeting the centrosome and polo-like kinase 4 in osteosarcoma
Fergal C Kelleher1,2, Jeska Kroes1, Jeremy Lewin3
1Department of Medical Oncology, St. James Hospital, Dublin, Ireland.
Abstract:
It has been historically uncertain if extra centrosomes are a cause or consequence of tumorigenesis. Experiments have recently established that overexpression of polo-like kinase 4 (PLK4) promotes centrosome amplification with consequential promotion of cellular aneuploidy. Furthermore, centrosome amplification drives spontaneous tumorigenesis in mice. Tissues lacking normal functional p53 tolerate extra centrosomes, whereas p53 proficient tissues initiate proliferative arrest in this circumstance. Extra centrosomes trigger activation of the multi-protein PIDDosome complex, with Caspase-2 effecting cleavage of the p53-negative regulator mouse double minute 2, consequent stabilization of p53 and p21-dependent arrest of the cell cycle. The co-occurrence of cellular aneuploidy, complex chromosomal rearrangements and p53 dysfunction is a striking feature of some osteosarcomas. It is postulated that small-molecule PLK4 inhibitors such as CFI-400945, which are in development, may have utility in osteosarcoma given these findings.
Insights
Extra centrosomes, driven by polo-like kinase 4 (PLK4), promote tumorigenesis and aneuploidy. Functional p53 halts cell cycle in response, suggesting PLK4 inhibitors like CFI-400945 may treat osteosarcomas.
Area of Science:
- Cell Biology
- Cancer Biology
- Genetics
Background:
- The role of extra centrosomes in tumorigenesis has been debated.
- Polo-like kinase 4 (PLK4) overexpression induces centrosome amplification and aneuploidy.
- Centrosome amplification is linked to spontaneous tumor formation in mice.
Purpose of the Study:
- To investigate the link between PLK4, centrosome amplification, and tumorigenesis.
- To explore the role of p53 in response to extra centrosomes.
- To evaluate the potential of PLK4 inhibitors in osteosarcoma treatment.
Main Methods:
- Overexpression of PLK4 to induce centrosome amplification.
- Analysis of cellular aneuploidy and tumor formation in mice.
- Investigation of p53 pathway activation and cell cycle arrest.
- Examination of osteosarcoma tissues for associated genetic features.
Main Results:
- PLK4 overexpression leads to centrosome amplification, aneuploidy, and tumorigenesis.
- p53-deficient tissues tolerate extra centrosomes, while p53-proficient tissues arrest proliferation.
- Extra centrosomes activate the PIDDosome complex, leading to p53 stabilization and cell cycle arrest.
- Osteosarcomas exhibit aneuploidy, chromosomal rearrangements, and p53 dysfunction.
Conclusions:
- PLK4-induced centrosome amplification is a driver of tumorigenesis.
- The p53 pathway acts as a critical barrier against extra centrosomes.
- PLK4 inhibitors, such as CFI-400945, show potential therapeutic value for osteosarcoma.
Related Concept Videos
Protein Kinases and Phosphatases
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
Protein Kinases and Phosphatases
Centrioles and Centrosomes
Near the end of the prophase, also called late prophase or...
Centrosome Duplication
To ensure that each daughter cell receives a centrosome after cell division, centrosome duplication...
Receptor Tyrosine Kinases
Dipeptidyl Peptidase 4 Inhibitors

